Therefore, we conclude that TNFSF14-derived molecules may improve glucose homeostasis and lipid metabolism and may therefore open a completely novel therapeutic pathway for treating obesity and T2D. This evidence concerns the gene TNFSF14 and obesity due to melanocortin 4 receptor deficiency.